Följ
Johan Haux
Johan Haux
MD, PhD. Överläkare, Consultant in Medical Oncology, Skas Skövde
Verifierad e-postadress på vgregion.se - Startsida
Titel
Citeras av
Citeras av
År
Digitoxin is a potential anticancer agent for several types of cancer
J Haux
Medical hypotheses 53 (6), 543-548, 1999
2051999
Digitoxin medication and cancer; case control and internal dose-response studies
J Haux, O Klepp, O Spigset, S Tretli
BMC cancer 1 (1), 1-6, 2001
1712001
Regulation of APO-2 ligand/trail expression in NK cells—involvement in NK cell-mediated cytotoxicity
AC Johnsen, J Haux, B Steinkjer, U Nonstad, K Egeberg, A Sundan, ...
Cytokine 11 (9), 664-672, 1999
1201999
Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity
AE Medvedev, AC Johnsen, J Haux, B Steinkjer, K Egeberg, DH Lynch, ...
Cytokine 9 (6), 394-404, 1997
1131997
Digitoxin, in non toxic concentrations, induces apoptotic cell death in Jurkat T cells in vitro
J Haux, M Lain, ABL Marthinsen, T Strickert, S Lundgren
ZEITSCHRIFT FUR ONKOLOGIE 31, 14-14, 1999
451999
Digitoxin, in non-toxic concentrations, inhibits proliferation and induces cell death in prostate cancer cell lines
J Haux, O Solheim, T Isaksen, A Angelsen
Zeitschrift für Onkologie 32 (01), 11-16, 2000
332000
The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis
J Haux, AC Johnsen, B Steinkjer, K Egeberg, A Sundan, T Espevik
Cancer Immunology, Immunotherapy 48 (2), 139-146, 1999
261999
Digitalis; impinges on more than just the (ion-) pump
J Haux
Medical hypotheses 59 (6), 781-782, 2002
132002
The dynamics of cell proliferation
JF Moxnes, J Haux, K Hausken
Medical hypotheses 62 (4), 556-563, 2004
122004
Infection and cancer
J Haux
The Lancet 358 (9276), 155-156, 2001
122001
Digitoxin sensitizes malignant breast cancer cells for radiation in vitro
J Haux, ABL Marthinsen, M Gulbrandsen, AS Alfredsen, H Johansen, ...
ZEITSCHRIFT FUR ONKOLOGIE 31, 61-65, 1999
101999
Digitoxin has specific properties for potential use to treat cancer and inflammatory diseases
J Haux
Res & Rev Health Care Open Acc J 2 (3), 2018
32018
ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin±bevacizumab in patients with metastasizing colorectal cancer
GU Carlsson, TK Guren, J Haux, P Pfeiffer, H Taflin, D Mavroudis, ...
Annals of Oncology 29, viii190, 2018
2018
ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin±bevacizumab in patients with metastasizing colorectal cancer.
HA Taflin, KME Ganlov, TK Guren, C Papadimitrou, NK Kentepozidis, ...
Journal of Clinical Oncology 36 (4_suppl), 838-838, 2018
2018
ISO-005; An open-label, multiple-site, dose cohort, phase I/II study in patients with stage IV colorectal cancer.
HA Taflin, Y Wettergren, E Odin, J Haux, B Gustavsson, GU Carlsson
Journal of Clinical Oncology 35 (4_suppl), TPS811-TPS811, 2017
2017
Induksjon av kreftcelledød
J Haux
Tidsskrift for Den norske legeforening, 2003
2003
Article Title: The Dynamics of War between Benign and Malignant Cells
JF Moxnes, K Hausken, J Haux
Article Title: The Dynamics of Cell Proliferation
JF Moxnes, J Haux, K Hausken
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–18